Zenas BioPharma eyes 2026 commercial launch following Phase 3 obexelimab success

Zenas BioPharma (NASDAQ:ZBIO) announced its full-year 2025 financial results on March 16, 2026, marking a pivotal year that has positioned the Waltham, Massachusetts-based biotech for its first potential product launch.

The company’s lead candidate, obexelimab, achieved its primary endpoint in the Phase 3 INDIGO registrational trial for Immunoglobulin G4-related disease (IgG4-RD).

The data revealed a statistically significant 56% reduction in the risk of disease flares compared to placebo, with a compelling safety profile that showed no new signals over the 52-week study period.

Armed with these results, Zenas is moving aggressively toward regulatory filings.

The company confirmed it remains on track to submit a Biologics License Application (BLA) to the FDA in the second quarter of 2026, followed by a Marketing Authorization Application (MAA) to the EMA in the second half of the year.

Obexelimab's unique mechanism—which inhibits B cells via CD19 and FcγRIIb without depleting them—along with its at-home subcutaneous administration, is expected to differentiate it as a first-in-class option for the roughly 20,000 to 40,000 patients in the U.S. currently lacking approved therapies.

Financial highlights for 2025 reflect the high cost of running global Phase 3 programs.

Zenas reported a net loss of $377.7 million for the year, compared to a $157 million loss in 2024.

Revenue for the year was $10 million, primarily derived from an upfront payment in a licensing agreement with Zai Lab.

However, the company significantly bolstered its balance sheet in March 2026 by securing a five-year, $250 million senior secured debt facility from Pharmakon Advisors.

This facility, combined with year-end cash and investments of $360.5 million, provides a capital runway that management expects will support operations into 2027.

Beyond its lead indication, Zenas is expanding the obexelimab franchise.

Topline results from the Phase 2 SunStone trial in systemic lupus erythematosus (SLE) are expected in the fourth quarter of 2026.

The company also recently presented Phase 2 data in multiple sclerosis showing a 95% reduction in brain lesions, further validating its B-cell inhibition platform.